Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dienogest

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dienogest
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Menorrhagia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Pregnadien derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dienogest in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dienogest with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist and Progestin-primed Ovarian Stimulation (PPOS) in Controlled Ovarian Stimulation for in Vitro Fertilization: a Prospective Comparative Observational Study

    NCT07732348 · start 2026-09

    Registered record
    Registry ID
    NCT07732348
    Conditions
    Infertility, Female; Ovulation Induction
    Interventions
    Ganirelix; Cetrorelix; Medroxyprogesterone Acetate; Dienogest; Micronized Progesterone; Linzagolix
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2026-12
    Enrolment
    195

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility, Female; Ovulation Induction
    InterventionGanirelix; Cetrorelix; Medroxyprogesterone Acetate; Dienogest +2 more
    PhaseNot recorded
    Registry statusNot yet recruiting

  • MRI-Based Prediction of Dienogest Response in Endometriosis

    NCT07446608 · start 2025-10-14

    Registered record
    Registry ID
    NCT07446608
    Conditions
    Endometriosis, Ovarian
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-10-14
    Completion
    2027-03
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis, Ovarian
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Guangdong Endometriosis Retrospective Clinical Cohort

    NCT07519213 · start 2025-09-01

    Registered record
    Registry ID
    NCT07519213
    Conditions
    Ovarian Endometrioma; Endometriosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2025-09-01
    Completion
    2026-01-01
    Enrolment
    1,121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Endometrioma; Endometriosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis

    NCT07204093 · start 2025-08-11

    Registered record
    Registry ID
    NCT07204093
    Conditions
    Endometriosis
    Interventions
    Drospirenone 4 mg orally; Dienogest 2 mg orally
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-08-11
    Completion
    2026-02
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionDrospirenone 4 mg orally; Dienogest 2 mg orally
    PhaseNot recorded
    Registry statusActive not recruiting

  • Effect of Dienogest in Symptomatic Endometrioma in Comparison to Combined Oral Contraceptive Pill.

    NCT07770594 · start 2025-04-17

    Registered record
    Registry ID
    NCT07770594
    Conditions
    Endometrioma
    Interventions
    Tab.Dienogest 2 mg; Combined oral contraceptive pill (ethinyl estradiol,30mcg+desogestrel,150mcg) tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-04-17
    Completion
    2026-04-16
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrioma
    InterventionTab.Dienogest 2 mg; Combined oral contraceptive pill (ethinyl estradiol,30mcg+desogestrel,150mcg) tablet
    PhaseNot applicable
    Registry statusCompleted

  • Evaluation of Anterior Tibial Knee Translation in Healthy Women With and Without Hormone Therapy

    NCT06504953 · start 2024-08-01

    Registered record
    Registry ID
    NCT06504953
    Conditions
    Women; Tibial Translation; Hormone
    Interventions
    Questionnaire; Beighton test; Lachman Test
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-08-01
    Completion
    2026-06-17
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWomen; Tibial Translation; Hormone
    InterventionQuestionnaire; Beighton test; Lachman Test
    PhaseNot applicable
    Registry statusCompleted

  • Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis

    NCT06543550 · start 2024-07-30

    Registered record
    Registry ID
    NCT06543550
    Conditions
    Endometriosis
    Interventions
    Implantable gestrinone; Oral Dienogest
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-07-30
    Completion
    2025-10
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionImplantable gestrinone; Oral Dienogest
    PhasePhase 4
    Registry statusUnknown

  • Role of Medical Treatment in Endometriosis Patients Undergoing ICSI

    NCT06577974 · start 2024-07-01

    Registered record
    Registry ID
    NCT06577974
    Conditions
    Endometriosis
    Interventions
    Combined contraceptive pills (Yasmin)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-07-01
    Completion
    2025-03-01
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionCombined contraceptive pills (Yasmin)
    PhaseNot applicable
    Registry statusUnknown

  • "Quick-starting" of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition

    NCT06396208 · start 2024-05-09

    Registered record
    Registry ID
    NCT06396208
    Conditions
    Ultrasound Finding: Ovulation Inhibition, Ovarian Activities; Cervical Mucus; Serum Hormonal Profile
    Interventions
    Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2); Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-05-09
    Completion
    2024-10-20
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUltrasound Finding: Ovulation Inhibition, Ovarian Activities; Cervical Mucus; Serum Hormonal Profile
    InterventionQuadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2); Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)
    PhaseNot applicable
    Registry statusCompleted

  • Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy

    NCT06414720 · start 2024-04-22

    Registered record
    Registry ID
    NCT06414720
    Conditions
    Endometriosis
    Interventions
    Dienogest 2 MG
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-04-22
    Completion
    2025-12-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionDienogest 2 MG
    PhaseNot recorded
    Registry statusRecruiting

  • Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery

    NCT06145438 · start 2023-09-04

    Registered record
    Registry ID
    NCT06145438
    Conditions
    Endometriosis Ovary
    Interventions
    Dienogest; Depo Medroxyprogesterone acetate; Leuprolide (as Leuprolide Acetate); Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-09-04
    Completion
    2024-11-19
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis Ovary
    InterventionDienogest; Depo Medroxyprogesterone acetate; Leuprolide (as Leuprolide Acetate); Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon)
    PhasePhase 3
    Registry statusCompleted

  • Comparisons of the Therapeutic Effects of Dienogest and Danazol on Endometriosis

    NCT05697471 · start 2023-02-25

    Registered record
    Registry ID
    NCT05697471
    Conditions
    Endometriosis
    Interventions
    Dienogest; Danazol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-02-25
    Completion
    2025-12-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionDienogest; Danazol
    PhasePhase 3
    Registry statusUnknown

  • The Use of Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation

    NCT06316206 · start 2023-01-01

    Registered record
    Registry ID
    NCT06316206
    Conditions
    Endometrial Polyp; Endometrial Diseases
    Interventions
    Ethinylestradiol/Dienogest 0.03mg/2mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-01-01
    Completion
    2024-03-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Polyp; Endometrial Diseases
    InterventionEthinylestradiol/Dienogest 0.03mg/2mg
    PhasePhase 4
    Registry statusCompleted

  • A Study to Gather Information About User Satisfaction in Women in Russia Who Take Estradiol Valerate/Dienogest

    NCT04901377 · start 2021-06-24

    Registered record
    Registry ID
    NCT04901377
    Conditions
    Oral Contraception
    Interventions
    Estradiol valerate/ Dienogest
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-06-24
    Completion
    2023-04-20
    Enrolment
    255

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Contraception
    InterventionEstradiol valerate/ Dienogest
    PhaseNot recorded
    Registry statusCompleted

  • Goserline Acetate VS Dienogest in Endometriosi

    NCT05013242 · start 2020-12-25

    Registered record
    Registry ID
    NCT05013242
    Conditions
    Endometriosis
    Interventions
    Zoladex; Visanne
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-12-25
    Completion
    2021-12-25
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionZoladex; Visanne
    PhasePhase 4
    Registry statusUnknown